NeuroPace Wins FDA Approval for AI-Powered Epilepsy Tool
MOUNTAIN VIEW, Calif., May 29, 2026 NeuroPace, Inc., a leading medical technology company focused on transforming the treatment of...
Neurology
Advertisement
Merz Therapeutics Unveils New Insights Into Parkinson’s OFF Episodes at WPC 2026
FRANKFURT, Germany & RALEIGH, N.C. — May 28, 2026 Merz Therapeutics presented new research at the World Parkinson Congress...
Ono Pharma Highlights New Phase 2 MSA Data
OSAKA, Japan — May 28, 2026 Ono Pharmaceutical Co., Ltd. announced the presentation of new clinical data from its...
Emalex Ecopipam Phase 3 Tourette Data Published
CHICAGO, Ill., May 26, 2026 Emalex Biosciences announced that Phase 3 clinical data for ecopipam, its investigational dopamine-1 (D1)...
Persistence Market Research Predicts CGRP Inhibitors Market to Reach $12.5B
London, United Kingdom, May 25, 2026 The global market for CGRP inhibitors, one of the fastest-growing classes of migraine...
Advertisements
Teva Uncovers Widespread Underdiagnosis of Tardive Dyskinesia in Young Patients
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 Teva Pharmaceuticals has announced new findings from its ongoing IMPACT-TD...
Encoded Therapeutics Reports Strong ETX101 Results
SOUTH SAN FRANCISCO, Calif. – May 13, 2026 Encoded Therapeutics presented expanded clinical data from its ongoing POLARIS Phase...
Neurogene Highlights Rett Gene Therapy Progress at ASGCT
NEW YORK, May 12, 2026 Neurogene presented new data at the 2026 American Society of Gene and Cell Therapy...
Encoded Therapeutics Expands CNS Gene Therapy Pipeline
SOUTH SAN FRANCISCO, Calif., May 12, 2026 Encoded Therapeutics announced new preclinical findings at the 2026 American Society of...
Argenx Gains FDA Approval Expanding VYVGART to All gMG Patients
AMSTERDAM, Netherlands, May 8, 2026 Argenx SE announced that the U.S. Food and Drug Administration (FDA) has approved a...
Advertisement
